Novartis weekly recap: Avidity $12B deal and trial setbacks
Recap highlights Novartis’ strategy including buying Avidity for $12B and clinical trial setbacks, alongside governance activism and a reported HSBC price-target lift.
Site Search
Search market news
Find public news by keyword, exact ticker, category and date.
Matching instruments
Open a ticker page for its news coverage. The news search below stays a text search.